RISE IN DEHYDROEPIANDROSTERONE AND OESTROGENS DURING CLOMIPHENE ADMINISTRATION IN NORMAL MEN

1976 ◽  
Vol 83 (1) ◽  
pp. 166-172 ◽  
Author(s):  
J. P. Kampmann ◽  
F. Schønau Jørgensen ◽  
E. P. Bennett ◽  
Svend G. Johnsen
Keyword(s):  
Urinary Excretion ◽  
Clomiphene Citrate ◽  
Serum Testosterone ◽  
Daily Administration ◽  
Independent Effect ◽  
Serum Concentrations ◽  
Testosterone Concentration ◽  
Adrenal Steroidogenesis ◽  
Free Cortisol ◽  
Normal Men

ABSTRACT Serum concentrations of LH, FSH and testosterone, and urinary excretion of individual 17-ketosteroids, oestrogenic substances and free cortisol was investigated in 12 normal men after a daily administration of 50 mg clomiphene citrate for 14 days. A significant increase in the serum concentrations of LH, FSH and testosterone was seen after 8 days with a further increase when measured a week later. The percentual increase in urinary excretion of oestrogens and dehydroepiandrosterone was of the same order as the increase in serum testosterone concentration whereas the increase in androsterone and a aetiocholanolone was significantly lower. The excretion of free cortisol was unaltered. The study indicates that measurements of oestrogens in the urine might be used as a parameter of the stimulatory effect of clomiphene on the hypothalamic - pituitary - gonadal axis in man. In addition, the results support the hypothesis of an independent effect of clomiphene on adrenal steroidogenesis, not related to the production of glucocorticoids.

The effect of cyproterone acetate on serum lipids in normal men

1980 ◽  
Vol 94 (2) ◽  
pp. 280-283 ◽  
Author(s):  
Finn Damgaard-Pedersen ◽  
Marie Føgh
Keyword(s):  
Cyproterone Acetate ◽  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Serum Testosterone ◽  
Tolerance Test ◽  
Low Doses ◽  
Testosterone Concentration ◽  
Fat Tolerance Test ◽  
Normal Men ◽  
Atherosclerotic Risk Factors

Abstract. In a male anti-fertility study 7 volunteers received the anti-androgen cyproterone acetate (5 or 10 mg daily) orally in a paired study. A significant reduction in serum-cholesterol and LDL-cholesterol, and a significant increase in the intravenous-fat-tolerance-test (IVFTT) was observed. Thus low doses of cyproterone acetate reduced the serum testosterone concentration and some of the atherosclerotic risk factors.

An investigation of LH pulsatility in burned men by bioassay and radioimmunoassay

1992 ◽  
Vol 126 (5) ◽  
pp. 404-409 ◽  
Author(s):  
CG Semple ◽  
R Mitchell ◽  
S Hollis ◽  
WR Robertson
Keyword(s):  
Biological Activity ◽  
Serum Testosterone ◽  
Normal Subjects ◽  
Published Data ◽  
Blood Samples ◽  
Testosterone Concentration ◽  
Lh Pulsatility ◽  
Pulse Peak ◽  
The Mean ◽  
Normal Men

LH pulsatility studies were performed in six burned patients by removing blood samples at 10 min intervals over a 6 h period. All samples were assayed for LH by bioassay (B-LH), LH by radioimmunoassay (I-LH) and testosterone. Mean serum testosterone concentrations of the burned patients were low (6.7±1.6 nmol/l). I-LH levels were lower than B-LH in all samples. Frequency of bioactive or immunoreactive pulses as well as mean B-LH and I-LH concentrations were similar to previously published data from normal men examined in the same laboratory. The mean biological activity of LH (expressed as the ratio of B-LH to I-LH, the B:I ratio) was lower in burned subjects (1.9±0.1) than previously reported in normal men. The B:I ratios of burned men were lower (p <0.01) at pulse peaks than at nadirs (1.8±0.1 vs 2.0±0.1) and an increase in serum testosterone concentration did not follow an LH peak. Serum testosterone concentrations did not cross-correlate with B-LH or I-LH. This contrasts with the findings in normal subjects where the B:I ratios have been found to be higher at pulse peaks than at nadirs and an increase in serum testosterone concentration follows a pulse peak and serum testosterone cross-correlates with B-LH and I-LH. LH secreted in a pulse peak in normal men may contain a particularly biologically potent form of the molecule but this may not be the case in burned men.

scholarly journals Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men

2002 ◽  
pp. 673-679 ◽  
Author(s):  
C Rolf ◽  
S Kemper ◽  
G Lemmnitz ◽  
U Eickenberg ◽  
E Nieschlag
Keyword(s):  
Day Treatment ◽  
Randomized Study ◽  
Serum Testosterone ◽  
Pharmacokinetic Profile ◽  
Serum Concentrations ◽  
Female Partners ◽  
Replacement Treatment ◽  
Physiological Serum ◽  
Testosterone Gel ◽  
Normal Men

OBJECTIVE: In a phase I single-centre, open, randomized study, the pharmacokinetics of two doses of a transdermal testosterone gel containing 2.5% testosterone were evaluated in 26 healthy male volunteers. DESIGN: To eliminate the influence of endogenous serum testosterone, gonadotrophins and endogenous testosterone secretion were suppressed by a single intramuscular injection of 400 mg norethisterone enanthate. Fourteen men applied 5.0 g and 12 men applied 2.5 g testosterone gel daily for 10 days. Half the men in each group washed the gel off 10 min after it had been applied. RESULTS: In all the men, a marked suppression of LH, FSH, testosterone, dihydrotestosterone (DHT) and oestradiol was observed after norethisterone treatment. Physiological serum concentrations of testosterone were restored during the 10-day treatment period in the group of men applying 5.0 g testosterone gel. Increasing serum concentrations of testosterone from day 1 to day 10 were observed. Oestradiol and DHT concentrations did not exceed normal values. Washing 10 min after gel application did not influence the resorption of testosterone. A dose of 2.5 g testosterone gel was insufficient to achieve physiological serum concentrations of testosterone. CONCLUSION: Testosterone replacement treatment with 5.0 g of this 2.5% testosterone gel is able to achieve constant physiological testosterone concentrations in gonadotrophin-suppressed men. Washing the skin after 10 min does not influence the pharmacokinetic profile and thus significantly reduces the risk of contamination of female partners or infants.

Decrease in serum testosterone concentration during treatment with tetracycline

1983 ◽  
Vol 103 (2) ◽  
pp. 269-272 ◽  
Author(s):  
M. O. Pulkkinen ◽  
J. Mäenpää
Keyword(s):  
Binding Capacity ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
Serum Concentrations ◽  
Hormone Binding ◽  
Testosterone Concentration ◽  
Tetracycline Treatment ◽  
Cessation Of Treatment

Abstract. Serum concentrations of testosterone and the binding capacity of sex hormone binding globulin (SHBG) were measured on 2 days immediately preceding tetracycline treatment, on 3 days of treatment and on 2 days immediately after cessation of treatment. On the treatment days serum mean testosterone concentrations were significantly lower than on the control days (17 ± 0.9 vs 21 ± 0.8 nmol/l, P < 0.01). There were no differences in the SHBG. The 'free testosterone index' behaved like the total testosterone.

ÉTUDES IN VIVO SUR LE MÉTABOLISME DES ANDROGÉNES APRES ADMINISTRATION DE STÉROÏDES INHIBITEURS DE L'OVULATION

1965 ◽  
Vol 50 (1) ◽  
pp. 131-144 ◽  
Author(s):  
P. Mauvais-Jarvis ◽  
M. F. Jayle ◽  
J. Decourt ◽  
J. Louchart ◽  
J. Truffert
Keyword(s):  
Luteinizing Hormone ◽  
Urinary Excretion ◽  
Normal Subjects ◽  
Hormone Activity ◽  
Testosterone Production ◽  
Normal Men ◽  
Ethinyl Oestradiol

ABSTRACT Normal subjects and hirsute women with micropolycystic ovaries were treated with ethinyl-oestrenol + 3-methoxy-ethinyl-oestradiol (Lyndiol®), in view of studying the action of this compound on the production of androgens and on the urinary excretion of their metabolites. In normal men, the production of testosterone and the excretion of androsterone and aetiocholanolone are suppressed, whereas the excretion of other 17-ketosteroids and the production of dehydroepiandrosterone sulphate are unchanged. Moreover, the luteinizing hormone activity (LH) in plasma is depressed. It seems that the preparation inhibits specifically the testicular androgen production, by suppressing the hypothalamo-hypophyseal control of LH. Testosterone production and urinary 17-ketosteroid excretion are modified in the same way in women with Stein-Leventhal's syndrome. Physiopathological and therapeutical implications which come from these results are discussed.

URINARY EXCRETION OF FREE CORTISOL IN HYPERCALCAEMIA

1973 ◽  
Vol 74 (1) ◽  
pp. 122-126 ◽  
Author(s):  
F. Schønau Jorgensen ◽  
H. Kehlet
Keyword(s):  
Urinary Excretion ◽  
Hpa Axis ◽  
Animal Studies ◽  
Urinary Cortisol ◽  
Free Cortisol ◽  
Free Urinary Cortisol ◽  
Urinary Cortisol Excretion ◽  
Cortisol Excretion

ABSTRACT Human and animal studies have uniformly demonstrated increased hypothalamic-pituitary-adrenocortical (HPA) activity during acute hypercalcaemia. The HPA-activity during chronic hypercalcaemia was investigated by means of free urinary cortisol excretion. No difference in HPA activity could be demonstrated between a hyperparathyroid hypercalcaemic and a normocalcaemic group of patients. Based on these results it is suggested that during chronic hypercalcaemia, the HPA feed back mechanism overcomes the influence of hypercalcaemia on the HPA-axis.

Social Dominance and Serum Testosterone Concentration in Dyads of Male Macaca fascicularis

1986 ◽  
Vol 15 (6) ◽  
pp. 419-432 ◽  
Author(s):  
Margaret R. Clarke ◽  
Jay R. Kaplan ◽  
Patricia T. Bumsted ◽  
Donald R. Koritnik
Keyword(s):  
Social Dominance ◽  
Macaca Fascicularis ◽  
Serum Testosterone ◽  
Testosterone Concentration

Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men

1983 ◽  
Vol 102 (3) ◽  
pp. 456-462 ◽  
Author(s):  
Th. Schürmeyer ◽  
E. J. Wickings ◽  
C. W. Freischem ◽  
E. Nieschlag
Keyword(s):  
Interindividual Variability ◽  
Serum Testosterone ◽  
Serum Samples ◽  
Additional Increase ◽  
Testosterone Undecanoate ◽  
Absorption Pattern ◽  
High Interindividual Variability ◽  
Normal Men ◽  
Hydrolysis Of ◽  
Testosterone Ester

Abstract. Since saliva testosterone reflects the testosterone fraction available to target tissues the therapeutic effectiveness of orally administered testosterone undecanoate was assessed by measuring testosterone in serum and saliva. Matched saliva and serum samples were obtained from 12 normal men and 8 hypogonadal men before and at hourly intervals after the oral administration of 120 mg testosterone undecanoate. The test was repeated in 3 men after they had taken 40 mg testosterone undecanoate twice daily for 4 to 5 weeks. Following testosterone undecanoate administration serum and saliva testosterone always showed parallel increases. However, the absorption curves showed a high interindividual variability in the time when maximum concentrations were reached, as well as in the maximum levels themselves. The increases in serum and saliva testosterone were similar in normal and hypogonadal men. In normal men basal levels were reached 4 h after the maximum had occurred, while in hypogonadal men testosterone levels were not different from basal levels 2 h after the maximum. The study shows that testosterone undecanoate is well absorbed from the gut and releases significantly elevated amounts of testosterone which is available to target tissues. As the absorption pattern was always parallel in both fluids, hydrolysis of the circulating testosterone ester by the tissue ifself seems to effect no additional increase of testosterone in the tissue.

Impact of Clomiphene Citrate on the Steroid Profile in Dysmetabolic Men with Low Testosterone Levels

2021 ◽  
Vol 53 (08) ◽  
pp. 520-528
Author(s):  
Carla Pelusi ◽  
Flamina Fanelli ◽  
Margherita Baccini ◽  
Giovanni De Pergola ◽  
Vincenzo Triggiani ◽  
...  
Keyword(s):  
Clomiphene Citrate ◽  
Serum Levels ◽  
Male Hypogonadism ◽  
Hormonal Changes ◽  
Double Blind ◽  
Adrenal Steroidogenesis ◽  
Steroid Profiling ◽  
Corticosteroid Binding Globulin ◽  
Before And After ◽  
17Β Estradiol

AbstractClomiphene citrate (CC) in male hypogonadism increases testosterone (T) and estrogen levels by stimulating pituitary gonadotropin release. Our group confirmed these hormonal changes in a randomized, cross-over, double-blind trial of CC versus placebo in addition to metformin, conducted in 21 obese dysmetabolic men with low T levels. However, we hypothesize that based on its mechanism of action, CC may directly or indirectly affect adrenal steroidogenesis. The aim of this sub-study was to better understand the changes in steroid levels and metabolism induced by CC treatment. We assessed 17α-hydroxypregnelone (17αOH-P5), dehydroepiandrosterone (DHEA), progesterone (P4), 17α-hydroxyprogesterone (17αOH-P4), androstenedione (A), T, dihydrotestosterone (DHT), estrone (E1), 17β-estradiol (E2), 11-deoxycortisol (11 S), cortisol (F), and cortisone (E) by LC-MS/MS, and corticosteroid binding globulin (CBG) by ELISA, before and after each treatment. In addition, free-F and steroid product/precursor ratios were calculated. We observed a significant change in serum levels induced by CC compared with placebo for 17αOH-P4, DHT, T, E2, E1, F, E, and CBG, but not free-F. In addition, compared to placebo, CC induced higher 17αOH-P4/P4, E2/E1, 17αOH-P4/17αOH-P5, A/17αOH-P4, T/A, E1/A, F/11 S, and F/E ratios. Therefore, besides the CC stimulating effect on testis steroidogenesis, our study showed increased F, E, but not free-F, levels, indicating changes in steroid metabolism rather than adrenal secretion stimulation. The steroid profiling also revealed the CC stimulation of the Δ5 rather than the Δ4 pathway, thus indicating considerable testicular involvement in the increased androgen secretion.

Sign in / Sign up

Export Citation Format

Share Document